Among them is dupilumab, the first drug approved by the FDA for systemic AD treatment in 2017, opening up a new era of biological AD treatments.[6] Dupilumab is a fully human monoclonal antibody against IL-4Rα that blocks IL-4 and IL-13 signaling and has been shown to have good long-term efficacy and safety in treating children, adults, and older adult patients with AD in numerous clinical trials worldwide.[7] According to the diagnostic criteria of Hanifin and Rajka and the Scoring Atopic Dermatitis scale,[3] the patient was diagnosed with moderate AD. Here, IL13 is linked to atopic eczema.